Explore the Agenda
7:00 am Check In & Morning Coffee
7:45 am Chair’s Opening Remarks
Envisioning the Success of mRNA Therapeutics & Vaccines Enabled by Robust Biopharma Partnerships, Licensing & Capital Investment
7:55 am Biopharma Business Development & Investors Panel: Secure the Financial Future of mRNA Technology Through Trusting Investor Partnerships
8:35 am Session Reserved for ReciBiopharm
9:05 am A Look into the RNA Deals & Companies Landscape
9:15 am Advanced Patenting Considerations for mRNA Market Players & New Entrants
9:45 am Shaping the Future of mRNA Therapeutics: Scalable Innovations Across the RNA–LNP Workflow
10:15 am Morning Break & Networking
Discovery
Unravelling Novel Approaches for mRNA-LNP Delivery From Genetic Circuits to Gene Editing in Pre-Clinical Models – Chair
Director - self-amplifying Ribonucleic Acid team Lead, Johnson & Johnson
10:45 am RNA-based Genome Engineering by Target-Primed Reverse Transcription
Associate Director, Tessera Therapeutics
11:15 am Platinum® Pro Protein Barcoding: Advancing mRNA Drug Development through Multiplexed mRNA Screening with Direct Protein-Level Detection
Director - Technical Sales, Quantum Si
11:45 am Preclinical Evaluation of Targeted LNPs (tLNPs) for In Vivo HSC Delivery & Editing
Scientist, II, DMPK, Editas Medicine
Pre-Clinical Development
Clinical
Manufacturing & CMC
12:15 pm Lunch & Networking Break
Discovery
Unravelling Novel Approaches for Self-Amplifying RNA Technology Discoveries to Successfully Target the Tumour – Chair
Director - self-amplifying Ribonucleic Acid team Lead, Johnson & Johnson
1:15 pm STX-003: Targeting IL-12 Expression to Tumors via mRNA Programmed With Genetic Circuits
Senior Principal Scientist, Strand Therapeutics
1:45 pm dsRNA Control in mRNA Manufacturing：From Reduction to Detection
Project Manager, Vazyme
Pre-Clinical Development
Clinical
Manufacturing & CMC